SuperworthEnsysce Biosciences ENSC
- Market cap
- $9.2M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 2.0×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $4.5M
- −39% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- n/m
- not a meaningful number
Ensysce Biosciences trades at 2.0× sales. Its trailing earnings are negative, so it has no PE. Revenue was $4.5M over the last twelve months, down 39% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $435.4K+56% | $515K−64% | $305.7K−61% | $181.8K−63% | $3.4M+685% | $1.3M+153% | $1.3M+332% | $1.4M+654% | $493.1K−86% | $1.9M+44% | $961K−27% | $1.2M−15% | |
| R&D | $1.9M−60% | $2.2M−65% | $778.9K−57% | $947.2K−42% | $1.7M−12% | $3.8M+70% | $1.9M+142% | $1.9M+103% | $3M+75% | $3.6M−5% | $3.3M+78% | $2.5M+29% |
| SG&A | $1.2M−27% | $1.4M+21% | $1.4M−12% | $1.2M+4% | $1.1M−12% | $1.1M−25% | $1.4M+2% | $1.2M+1% | $1.3M+18% | $1.1M−2% | $1.2M−16% | $1.3M+6% |
| −$2.7M−56% | −$3.2M−49% | −$1.8M−28% | −$2M−15% | $644.7K | −$3.6M+13% | −$2M+7% | −$1.8M−11% | −$3.7M | −$2.8M−22% | −$3.6M+81% | −$2.6M+47% | |
| Interest expense | $7.6K+57% | $344.8K+565% | $1.2M+83271% | $27.6K | $4.1K−47% | $10.8K−97% | $3.9K−100% | $3.2K−89% | $6.4K+57% | $5.4K−50% | $3.9K+2% | $320−90% |
| Pre-tax income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$2.7M−73% | −$3.5M−36% | −$3.1M+42% | −$2M−12% | $661.8K | −$3.6M+2% | −$1.9M−38% | −$1.7M−12% | −$3.7M | −$2.8M−22% | −$3.6M+83% | −$2.6M+48% |
| −$13.05−99% | −$20.10−93% | −$8.21−74% | −$3.35−77% | $1.00 | −$2.90−86% | −$1.39−83% | −$0.79−76% | −$1.29 | −$0.75−74% | −$0.52−63% | −$0.20−75% | |
| 205.7K+1820% | 174.4K+767% | 379.6K+440% | 587.8K+288% | 659.4K+221% | 1.2M+606% | 1.4M+269% | 2.2M+275% | 2.9M+338% | 3.7M+202% | 6.8M+388% | 13M+492% |
EPS, diluted: 10 periods, Q4 FY18 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 7 periods, Q4 FY18 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY20: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Ensysce Biosciences' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ENSCEnsysce Biosciences | $9.2M | n/m | 96.0× | 2.0× | −39% | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on Ensysce Biosciences
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .